検索結果

therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed to improve both subjective symptoms and objective signs of DED through inhibition ...

therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed to improve both subjective symptoms and objective signs of DED through inhibition ...

quarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: To...

Publications | Research & Development | SENJU Pharmaceutica

1-11, 2026 Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease Tomoyuki Wada1, Kazunori Omatsu1, Stephen C. P...

Meetings of the Minds | Research & Development | SENJU Pharmaceutica

emy of Ophthalmology (APAO) Congress 開催日：2026年2月5日～2026年2月8日 開催地：Hong Kong Motugivatrep, a TRPV1 antagonist in Dry Eye Patients – Results of a Randomized, Double-Masked, Placebo-Controlled Phase 3 Piv...